MY ACCOUNT
Schizophrenia
Showing 1–12 of 1500 results
Development of Insomnia Associated With Different Formulations of Bupropion
In this brief report, the authors evaluate the effects of a possible association between different bupropion formulations and treatment-emergent insomnia in veterans with major depressive disorder prescribed bupropion based on provider discretion.
Olanzapine-Induced Aggression
Here, read about a 29-year-old woman who presented to our inpatient psychiatric facility for manic-like symptoms including pressured speech, flight of ideas, sexual preoccupations, and self-reported euphoria.
A Real-World Assessment of Outcomes in Schizophrenia Patients According to Treatment Response
To better understand the burden of partial treatment response on schizophrenia patients, their caregivers, and health care resources, this study compared demographics, outcomes, and comorbidities among schizophrenia patients with treatment response.
Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study
Transdermal asenapine administration may address unmet needs in patients with schizophrenia, including improved adherence. This phase 3 study assessed efficacy and safety of HP-3070, an asenapine transdermal system (patch), in adults with schizophrenia.
Lockdown and Psychosis: A Paranoid Delusion
Lockdown measures have helped contain the spread of COVID-19, but how do they affect mental health? This report describes a patient who developed a paranoid delusion caused by isolation, uncertainty, anxiety, and fear related to lockdown.
Temporal Lobe Epilepsy Mimicking Schizoaffective Disorder in Patients With Cavum Septi Pellucidi
Cavum septi pellucidi (CSP) is significantly more prevalent in individuals with mental illness than in healthy subjects. This report presents 3 cases of CSP and temporal lobe epilepsy-related psychosis previously misdiagnosed as schizoaffective disorder.
Visual Hallucinations After Treatment With Thiocolchicoside
This report presents a case in which a visually impaired patient describes the development of visual hallucinations after 2 oral administrations of thiocolchicoside.
Why COVID-19 Is Especially Difficult for Those With Schizophrenia: Reasons and Solutions
In this commentary, the authors address the impact of COVID-19 on patients with schizophrenia based on multiaxial diagnostic criteria and comment on the use of technology, telehealth, and other available strategies to mitigate the effects.
Aripiprazole-Induced Urinary Incontinence
Does aripiprazole induce urinary incontinence? The authors of this report describe a patient who developed acute urinary symptoms after treatment with aripiprazole for psychosis.
Who Has the Ability to Consent?
Does the capacity to consent vary between medical and psychiatric patients? Are tools needed to assess the patient's decision-making capacity, or can the provider's assessment be relied upon? Review the results of a study that sought answers to these questions in this CME journal activity.
Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study
Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
Second-Generation Antipsychotics and Pneumonia-Related Hospitalizations
Clozapine has been associated with pneumonia, but what about other agents? This study compared pneumonia hospitalization rates for patients with a psychotic or bipolar disorder prescribed 1 of 4 second-generation antipsychotics prior to admission.
